190 related articles for article (PubMed ID: 11289134)
1. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
2. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
4. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
7. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
[TBL] [Abstract][Full Text] [Related]
8. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy.
Ohmori T; Yang JL; Price JO; Arteaga CL
Exp Cell Res; 1998 Dec; 245(2):350-9. PubMed ID: 9851876
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein.
Reshetnikova G; Barkan R; Popov B; Nikolsky N; Chang LS
Exp Cell Res; 2000 Aug; 259(1):35-53. PubMed ID: 10942577
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
[TBL] [Abstract][Full Text] [Related]
11. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells.
Li WW; Fan J; Hochhauser D; Bertino JR
Cancer Res; 1997 Jun; 57(11):2193-9. PubMed ID: 9187120
[TBL] [Abstract][Full Text] [Related]
13. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53-independent p21 during ceramide-induced G1 arrest in human hepatocarcinoma cells.
Kim WH; Kang KH; Kim MY; Choi KH
Biochem Cell Biol; 2000; 78(2):127-35. PubMed ID: 10874474
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Almenara J; Rosato R; Grant S
Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
[TBL] [Abstract][Full Text] [Related]
16. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
17. Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6.
Ojala PM; Tiainen M; Salven P; Veikkola T; Castaños-Vélez E; Sarid R; Biberfeld P; Mäkelä TP
Cancer Res; 1999 Oct; 59(19):4984-9. PubMed ID: 10519412
[TBL] [Abstract][Full Text] [Related]
18. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
Said TK; Medina D
Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
[TBL] [Abstract][Full Text] [Related]
19. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
20. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]